Company Overview and News

9
TRIL / Trillium Therapeutics Inc. SUPPL

2018-06-20 sec.gov
Trilliuam Therapeutics Inc. - Prospectus Supplement - Filed by newsfilecorp.com Filed pursuant to General Instructions II.L. of Form F-10 File No. 333-222085 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the accompanying short form base shelf prospectus dated January 5, 2018 to which this prospectus supplement relates, as amended or supplemented, and each document deemed to be incorporated by ref
TRIL

9
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-20 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

11
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-20 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

22
Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement

2018-06-19 globenewswire
TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a sales agreement (“Sales Agreement”) with Cowen and Company, LLC (the “Agent”) pursuant to which the Company may, at its discretion and from time to time during the term of the Sales Agreement, sell, through the Agent, acting as agent and/or principal, such number of common shares of the Company (“Common Shares”) as would result in aggregate gross proceeds to the Company of up to US$25 million.
TRIL BR

9
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-18 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

164
Your Daily Pharma Scoop: Resverlogix Cleared For Trial, ViiV Positive Data, Eli Lilly Up

2018-06-16 seekingalpha
Resverlogix (OTCPK:RVXCF) recently announced that the FDA has accepted the statistical analysis plan and endpoints for the large-scale Phase 3 trial of assessment of cardiovascular benefits of its lead candidate apabetalone. The projected endpoint of the study is the reduction of major adverse cardiovascular events (MACE) in a high cardiovascular risk in type 2 diabetes population. The same population often also displayed low levels of high density lipoproteins (HDL).
CTRV AMGN RVXCF MTFB APTO MTFB APS LLY TRIL RYTM GSK MYL MTFBF INSY LIVN CHMA

7
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-15 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

7
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-14 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

288
BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth.
AUP EVFM PTLA AUPH DARE SRPT TRIL

10
Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer

2018-06-07 globenewswire
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today the appointment of Yaping Shou MD, PhD, as Chief Medical Officer. Dr. Shou joins Trillium from Takeda Pharmaceuticals.
TRIL

8
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-07 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

10
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-06-05 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2018
TRIL

18
TRIL / Trillium Therapeutics Inc. FORM F-3

2018-05-16 sec.gov
Trillium Therapeutics Inc.: Form F-3 - Filed by newsfilecorp.com As filed with the Securities and Exchange Commission on May 16, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRILLIUM THERAPEUTICS INC.
TRIL

6
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer)

2018-05-11 sec.gov
Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2018
TRIL

6
Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results

2018-05-11 globenewswire
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2018.
TRIL

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TRIL / Trillium Therapeutics Inc. on message board site Silicon Investor.

Trillium Therapeutics The World���s Biggest Wealth Fund Hits $1 Trillion
$20 Trillion in debt and more tax cuts? When will it end? Discuss the Fiscal Cliff. Obamau0027s opening bid: $1.6 trillion
CONSOLIDATED TRILOGY/CTJ/VSE: HUGE POTENTIAL IN CHILE. Go2Net Long List of Go2Netrillionaires (GNET)
Tri-Valley Corp. (OTC BB: TRIL) EKHO Project
Trillium BB Stocks Less Than 5 Cents with Trillion Share Floats
CUSIP: 89620X506